ahlam1399
08-18-2015, 11:38 PM
UPDATE 1-Amgen pays $71 mln to settle Enbrel, Aranesp marketing case
Aug 18 (Reuters) - Amgen Inc has reached a $71 million settlement with 48 U.S. states and the District of Columbia to resolve claims that the biotech**logy company promoted its popular Enbrel and Aranesp ***** for uses **t approved by the federal Food and Drug Administration.
http://rc.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/rc/1/rc.img (http://rc.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/rc/1/rc.htm)
http://rc.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/rc/2/rc.img (http://rc.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/rc/2/rc.htm)
http://rc.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/rc/3/rc.img (http://rc.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/rc/3/rc.htm)
http://da.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/a2.img (http://da.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/a2.htm)
http://adchoice.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/ach.img (http://adchoice.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/ach.htm)http://pi.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/a2t.imghttp://pi2.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/491663b3/sc/7/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=Yms86cYVcvI:JoC7cqI-phM:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Yms86cYVcvI:JoC7cqI-phM:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=Yms86cYVcvI:JoC7cqI-phM:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Yms86cYVcvI:JoC7cqI-phM:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=Yms86cYVcvI:JoC7cqI-phM:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/Yms86cYVcvI
Aug 18 (Reuters) - Amgen Inc has reached a $71 million settlement with 48 U.S. states and the District of Columbia to resolve claims that the biotech**logy company promoted its popular Enbrel and Aranesp ***** for uses **t approved by the federal Food and Drug Administration.
http://rc.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/rc/1/rc.img (http://rc.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/rc/1/rc.htm)
http://rc.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/rc/2/rc.img (http://rc.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/rc/2/rc.htm)
http://rc.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/rc/3/rc.img (http://rc.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/rc/3/rc.htm)
http://da.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/a2.img (http://da.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/a2.htm)
http://adchoice.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/ach.img (http://adchoice.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/ach.htm)http://pi.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/a2t.imghttp://pi2.feedsportal.com/r/234567337514/u/49/f/654213/c/35217/s/491663b3/sc/7/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/491663b3/sc/7/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=Yms86cYVcvI:JoC7cqI-phM:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Yms86cYVcvI:JoC7cqI-phM:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=Yms86cYVcvI:JoC7cqI-phM:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Yms86cYVcvI:JoC7cqI-phM:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=Yms86cYVcvI:JoC7cqI-phM:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/Yms86cYVcvI